Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1989 1
1993 1
1994 1
1995 1
1997 1
1998 1
1999 3
2001 1
2004 1
2005 1
2006 1
2007 2
2008 1
2009 6
2010 12
2011 9
2012 3
2013 12
2014 12
2015 8
2016 11
2017 11
2018 10
2019 15
2020 27
2021 25
2022 9
2023 28
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

197 results

Results by year

Filters applied: . Clear all
Page 1
Fcγ receptors and immunomodulatory antibodies in cancer.
Galvez-Cancino F, Simpson AP, Costoya C, Matos I, Qian D, Peggs KS, Litchfield K, Quezada SA. Galvez-Cancino F, et al. Among authors: matos i. Nat Rev Cancer. 2024 Jan;24(1):51-71. doi: 10.1038/s41568-023-00637-8. Epub 2023 Dec 7. Nat Rev Cancer. 2024. PMID: 38062252 Review.
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy.
Mayoux M, Roller A, Pulko V, Sammicheli S, Chen S, Sum E, Jost C, Fransen MF, Buser RB, Kowanetz M, Rommel K, Matos I, Colombetti S, Belousov A, Karanikas V, Ossendorp F, Hegde PS, Chen DS, Umana P, Perro M, Klein C, Xu W. Mayoux M, et al. Among authors: matos i. Sci Transl Med. 2020 Mar 11;12(534):eaav7431. doi: 10.1126/scitranslmed.aav7431. Sci Transl Med. 2020. PMID: 32161104
Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics.
Lozano-Rabella M, Garcia-Garijo A, Palomero J, Yuste-Estevanez A, Erhard F, Farriol-Duran R, Martín-Liberal J, Ochoa-de-Olza M, Matos I, Gartner JJ, Ghosh M, Canals F, Vidal A, Piulats JM, Matías-Guiu X, Brana I, Muñoz-Couselo E, Garralda E, Schlosser A, Gros A. Lozano-Rabella M, et al. Among authors: matos i. Clin Cancer Res. 2023 Jun 13;29(12):2250-2265. doi: 10.1158/1078-0432.CCR-22-3298. Clin Cancer Res. 2023. PMID: 36749875 Free PMC article.
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, Brose MS, Zhu VW, Leboulleux S, Bowles DW, Baik CS, Adkins D, Keam B, Matos I, Garralda E, Gainor JF, Lopes G, Lin CC, Godbert Y, Sarker D, Miller SG, Clifford C, Zhang H, Turner CD, Taylor MH. Subbiah V, et al. Among authors: matos i. Lancet Diabetes Endocrinol. 2021 Aug;9(8):491-501. doi: 10.1016/S2213-8587(21)00120-0. Epub 2021 Jun 9. Lancet Diabetes Endocrinol. 2021. PMID: 34118198 Clinical Trial.
Druggable Targets in Cytokine Release Syndromes.
Luri-Rey C, Eguren-Santamaria I, Matos I, Berraondo P, Melero I. Luri-Rey C, et al. Among authors: matos i. Clin Cancer Res. 2023 Nov 1;29(21):4320-4322. doi: 10.1158/1078-0432.CCR-23-1975. Clin Cancer Res. 2023. PMID: 37656058
Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
Adashek JJ, Subbiah IM, Matos I, Garralda E, Menta AK, Ganeshan DM, Subbiah V. Adashek JJ, et al. Among authors: matos i. Trends Cancer. 2020 Mar;6(3):181-191. doi: 10.1016/j.trecan.2020.01.005. Epub 2020 Feb 6. Trends Cancer. 2020. PMID: 32101722 Free PMC article. Review.
The safety of ramucirumab for the treatment of colorectal cancer.
Noguerido A, Mulet-Margalef N, Matos I, Ros J, Argilés G, Élez E, Tabernero J. Noguerido A, et al. Among authors: matos i. Expert Opin Drug Saf. 2018 Sep;17(9):945-951. doi: 10.1080/14740338.2018.1506762. Epub 2018 Aug 16. Expert Opin Drug Saf. 2018. PMID: 30073902 Review.
197 results